Top

International Journal of Clinical Oncology

Published in:

01-10-2021 | Pancreatic Cancer | Original Article

Frailty is associated with poor prognosis after resection for pancreatic cancer

Authors: Kosuke Mima, Hiromitsu Hayashi, Shigeki Nakagawa, Takashi Matsumoto, Shotaro Kinoshita, Kazuki Matsumura, Fumimasa Kitamura, Norio Uemura, Yosuke Nakao, Rumi Itoyama, Takayoshi Kaida, Katsunori Imai, Yo-ichi Yamashita, Hideo Baba

Published in: International Journal of Clinical Oncology | Issue 10/2021

Abstract

Background

With population aging, the number of frail patients with pancreatic cancer has increased. The Clinical Frailty Scale (CFS) is a simple and validated tool to assess frailty, and higher scores predict worse clinical outcomes after cardiovascular surgery. In this retrospective study, we aimed to examine the association of preoperative frailty with prognosis after resection for pancreatic cancer.

Methods

We retrospectively analyzed data from 142 consecutive patients undergoing resection for pancreatic cancer between April 2010 and December 2018. We used the CFS: 1 (very fit) to 9 (terminally ill) to assess frailty and examined associations of the CFS scores with recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs), controlling for potential confounders.

Results

Of the 142 patients, 113 (80%) had CFS scores of ≤ 3, 13 (9.2%) scores of 4, and 16 (11%) scores of ≥ 5. Scores of ≥ 5 on the CFS were associated with worse CSS (univariable HR: 2.62, 95% confidence interval [CI]: 1.19–5.18, P = 0.019; multivariable HR: 2.49, 95% CI 1.05–5.34, P = 0.039) and OS (univariable HR: 2.42, 95% CI 1.19–4.46, P = 0.016; multivariable HR: 2.25, 95% CI 1.05–4.43, P = 0.038). The association between CFS scores and RFS was not significant in multivariable analysis (univariable HR: 2.11, 95% CI 1.08–3.79, P = 0.030; multivariable HR: 1.47, 95% CI 0.71–2.83, P = 0.29).

Conclusion

Higher scores on the CFS are associated with worse CSS and OS after resection for pancreatic cancer. Preoperative measurement of frailty may improve risk assessment among patients with pancreatic cancer.

Available only for authorised users

Otsuka T, Shirakawa T, Shimokawa M et al (2021) A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol 26(5):941–950. https://doi.org/10.1007/s10147-021-01859-2CrossRefPubMed

Ishido K, Hakamada K, Kimura N et al (2021) Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 5(1):7–23. https://doi.org/10.1002/ags3.12379CrossRefPubMed

Yamaue H (2020) History of pancreatic surgery in Japan: Respect to the Japanese pioneers of pancreatic surgery. Ann Gastroenterol Surg 4(2):118–125. https://doi.org/10.1002/ags3.12320CrossRefPubMedPubMedCentral

Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2020) From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol 17(2):108–123. https://doi.org/10.1038/s41571-019-0281-6CrossRefPubMed

Lebenthal JM, Zheng J, Glare PA et al (2021) Prognostic value of the memorial sloan kettering prognostic score in metastatic pancreatic adenocarcinoma. Cancer 127(10):1568–1575. https://doi.org/10.1002/cncr.33420CrossRefPubMed

Strobel O, Neoptolemos J, Jager D et al (2019) Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol 16(1):11–26. https://doi.org/10.1038/s41571-018-0112-1CrossRefPubMed

Takeda T, Sasaki T, Fukuda K et al (2021) Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Int J Clin Oncol 26(3):543–551. https://doi.org/10.1007/s10147-020-01827-2CrossRefPubMed

Ikeda H, Togashi Y (2021) Aging, cancer, and antitumor immunity. Int J Clin Oncol. https://doi.org/10.1007/s10147-021-01913-zCrossRefPubMedPubMedCentral

Hoshino N, Aoyama R, Hida K (2021) Survival benefit of adjuvant chemotherapy in elderly patients with colon cancer: a systematic review and meta-analysis. Int J Clin Oncol 26(5):883–892. https://doi.org/10.1007/s10147-021-01858-3CrossRefPubMed

10.

Hamaya T, Hatakeyama S, Momota M et al (2021) Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study). Int J Clin Oncol 26(1):199–206. https://doi.org/10.1007/s10147-020-01798-4CrossRefPubMed

11.

Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet 381(9868):752–762. https://doi.org/10.1016/S0140-6736(12)62167-9CrossRefPubMed

12.

Carter B, Law J, Hewitt J et al (2020) Association between preadmission frailty and care level at discharge in older adults undergoing emergency laparotomy. Br J Surg 107(3):218–226. https://doi.org/10.1002/bjs.11392CrossRefPubMed

13.

Ethun CG, Bilen MA, Jani AB et al (2017) Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin 67(5):362–377. https://doi.org/10.3322/caac.21406CrossRefPubMed

14.

Takeda T, Sasaki T, Suzumori C et al (2021) The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol. https://doi.org/10.1007/s10147-021-01912-0CrossRefPubMedPubMedCentral

15.

Mima K, Miyanari N, Morito A et al (2020) Frailty is an independent risk factor for recurrence and mortality following curative resection of stage I-III colorectal cancer. Ann Gastroenterol Surg 4(4):405–412. https://doi.org/10.1002/ags3.12337CrossRefPubMedPubMedCentral

16.

Rockwood K, Song X, MacKnight C et al (2005) A global clinical measure of fitness and frailty in elderly people. CMAJ 173(5):489–495. https://doi.org/10.1503/cmaj.050051CrossRefPubMedPubMedCentral

17.

Rouge-Bugat ME, Gerard S, Balardy L et al (2013) Impact of an oncogeriatric consulting team on therapeutic decision-making. J Nutr Health Aging 17(5):473–478. https://doi.org/10.1007/s12603-012-0435-zCrossRefPubMed

18.

Miyata T, Hayashi H, Yamashita YI et al (2021) Prognostic value of the preoperative tumor marker index in resected pancreatic ductal adenocarcinoma: a retrospective single-institution study. Ann Surg Oncol 28(3):1572–1580. https://doi.org/10.1245/s10434-020-09022-3CrossRefPubMed

19.

Isaji S, Mizuno S, Windsor JA et al (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18(1):2–11. https://doi.org/10.1016/j.pan.2017.11.011CrossRefPubMed

20.

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369CrossRef

21.

Khorana AA, McKernin SE, Berlin J et al (2019) Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol 37(23):2082–2088. https://doi.org/10.1200/JCO.19.00946CrossRefPubMed

22.

Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13):1640–1648. https://doi.org/10.1200/JCO.2012.43.3680CrossRefPubMed

23.

Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257. https://doi.org/10.1016/S0140-6736(16)30583-9CrossRefPubMed

24.

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474

25.

Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2CrossRefPubMed

26.

Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 161(3):584–591. https://doi.org/10.1016/j.surg.2016.11.014CrossRefPubMed

27.

Okadome K, Baba Y, Yagi T et al (2020) Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg 271(4):693–700. https://doi.org/10.1097/SLA.0000000000002985CrossRefPubMed

28.

von Elm E, Altman DG, Egger M et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-XCrossRef

29.

Shimura T, Yamamoto M, Kano S et al (2017) Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation 135(21):2013–2024. https://doi.org/10.1161/CIRCULATIONAHA.116.025630CrossRefPubMed

30.

Muessig JM, Nia AM, Masyuk M et al (2018) Clinical frailty scale (CFS) reliably stratifies octogenarians in German ICUs: a multicentre prospective cohort study. BMC Geriatr 18(1):162. https://doi.org/10.1186/s12877-018-0847-7CrossRefPubMedPubMedCentral

31.

Sun CY, Huang CC, Tsai YS et al (2020) Clinical frailty scale in predicting postoperative outcomes in older patients undergoing curative surgery for urologic malignancies: a prospective observational cohort study. Urology 144:38–45. https://doi.org/10.1016/j.urology.2020.06.069CrossRefPubMed

32.

Beaubien-Souligny W, Yang A, Lebovic G et al (2021) Frailty status among older critically ill patients with severe acute kidney injury. Crit Care 25(1):84. https://doi.org/10.1186/s13054-021-03510-yCrossRefPubMedPubMedCentral

33.

Ngo-Huang A, Holmes HM, des Bordes JKA, et al (2019) Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Med 8(6):2867–2876. https://doi.org/10.1002/cam4.2157CrossRefPubMedPubMedCentral

34.

Dale W, Hemmerich J, Kamm A et al (2014) Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg 259(5):960–965. https://doi.org/10.1097/SLA.0000000000000226CrossRefPubMed

35.

Augustin T, Burstein MD, Schneider EB et al (2016) Frailty predicts risk of life-threatening complications and mortality after pancreatic resections. Surgery 160(4):987–996. https://doi.org/10.1016/j.surg.2016.07.010CrossRefPubMed

36.

Naito Y, Aburatani H, Amano T et al (2021) Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26(2):233–83. https://doi.org/10.1007/s10147-020-01831-6CrossRefPubMed

37.

Zhang Y, Xu Y, Wang D et al (2021) Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Int J Clin Oncol 26(1):135–144. https://doi.org/10.1007/s10147-020-01782-yCrossRefPubMed

38.

McIntyre CA, Lawrence SA, Richards AL et al (2020) Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer 126(17):3939–3949. https://doi.org/10.1002/cncr.33038CrossRefPubMed

39.

Collisson EA, Bailey P, Chang DK et al (2019) Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16(4):207–220. https://doi.org/10.1038/s41575-019-0109-yCrossRefPubMed

40.

Ho WJ, Jaffee EM, Zheng L (2020) The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat Rev Clin Oncol 17(9):527–540. https://doi.org/10.1038/s41571-020-0363-5CrossRefPubMedPubMedCentral

41.

Thomas RM, Jobin C (2020) Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nat Rev Gastroenterol Hepatol 17(1):53–64. https://doi.org/10.1038/s41575-019-0242-7CrossRefPubMed

42.

Li H, Manwani B, Leng SX (2011) Frailty, inflammation, and immunity. Aging Dis 2(6):466–473PubMedPubMedCentral

43.

Parker NH, Ngo-Huang A, Lee RE et al (2019) Physical activity and exercise during preoperative pancreatic cancer treatment. Support Care Cancer 27(6):2275–2284. https://doi.org/10.1007/s00520-018-4493-6CrossRefPubMed

44.

Nakajima H, Yokoyama Y, Inoue T et al (2019) Clinical benefit of preoperative exercise and nutritional therapy for patients undergoing hepato-pancreato-biliary surgeries for malignancy. Ann Surg Oncol 26(1):264–272. https://doi.org/10.1245/s10434-018-6943-2CrossRefPubMed

45.

Bundred JR, Kamarajah SK, Hammond JS et al (2020) Prehabilitation prior to surgery for pancreatic cancer: a systematic review. Pancreatology 20(6):1243–1250. https://doi.org/10.1016/j.pan.2020.07.411CrossRefPubMed

46.

Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35(5):515–522. https://doi.org/10.1200/JCO.2016.68.5081CrossRefPubMed

47.

Versteijne E, Suker M, Groothuis K et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 38(16):1763–1773. https://doi.org/10.1200/JCO.19.02274CrossRefPubMedPubMedCentral

48.

Maggino L, Malleo G, Marchegiani G et al (2019) Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg 154(10):932–942. https://doi.org/10.1001/jamasurg.2019.2277CrossRefPubMedPubMedCentral

49.

Macedo FI, Ryon E, Maithel SK et al (2019) Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg 270(3):400–413. https://doi.org/10.1097/SLA.0000000000003468CrossRefPubMed

50.

Motoi F, Unno M (2020) Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 4(2):100–108. https://doi.org/10.1002/ags3.12311CrossRefPubMedPubMedCentral

Title: Frailty is associated with poor prognosis after resection for pancreatic cancer
Authors: Kosuke Mima
Hiromitsu Hayashi
Shigeki Nakagawa
Takashi Matsumoto
Shotaro Kinoshita
Kazuki Matsumura
Fumimasa Kitamura
Norio Uemura
Yosuke Nakao
Rumi Itoyama
Takayoshi Kaida
Katsunori Imai
Yo-ichi Yamashita
Hideo Baba
Publication date: 01-10-2021
Publisher: Springer Singapore
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: International Journal of Clinical Oncology / Issue 10/2021
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-021-01983-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2021

Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck

Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma

Assessment of surgical outcomes of off-clamp open partial nephrectomy without renorrhaphy for ≥T1b renal tumours

Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma

Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario

Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer